STOCK TITAN
  1. Home
  2. Sec-filings
  3. ABEO
  4. [Form 4] ABEONA THERAPEUTICS INC. Insider Trading Activity

Tax-related stock sale by Abeona (ABEO) CEO leaves 1.31M shares

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Abeona Therapeutics Inc. chief executive officer Vishwas Seshadri reported an open-market sale of 67,971 shares of common stock at a weighted average price of $6.9637 per share. According to the filing, the sale was made to cover tax obligations from vesting restricted stock awards, and he continued to hold 1,306,108 shares afterward.

Positive

  • None.

Negative

  • None.
Insider Seshadri Vishwas
Role Chief Executive Officer
Sold 67,971 shs ($473K)
Type Security Shares Price Value
Sale Common Stock 67,971 $6.9637 $473K
Holdings After Transaction: Common Stock — 1,306,108 shares (Direct, null)
Footnotes (1)
  1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Shares sold 67,971 shares Open-market sale to cover tax obligations from vesting restricted stock awards
Weighted average sale price $6.9637 per share Common stock sale on transaction date
Post-transaction holdings 1,306,108 shares Common stock directly held after the sale
Price range of trades $6.86–$7.04 per share Multiple transactions contributing to the weighted average price
restricted stock awards financial
"tax obligations associated with the vesting of restricted stock awards"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Abeona Therapeutics (ABEO) CEO Vishwas Seshadri report on this Form 4?
The Abeona CEO reported selling 67,971 shares of common stock. The transaction was an open-market sale tied to tax obligations from vesting restricted stock awards, rather than a discretionary portfolio move.

At what price did the Abeona (ABEO) CEO sell his shares in this filing?
The reported weighted average sale price was $6.9637 per share. Footnotes state the 67,971 shares were sold in multiple trades between $6.86 and $7.04 per share, all on the same transaction date.

Why were Abeona Therapeutics (ABEO) shares sold by the CEO in this transaction?
The filing explains the sale was executed to cover tax obligations from vesting restricted stock awards. This means the transaction was primarily a tax-related event, not a standalone investment decision about Abeona’s future prospects.

How many Abeona (ABEO) shares does the CEO hold after this Form 4 transaction?
After selling 67,971 shares, the CEO directly held 1,306,108 shares of Abeona common stock. This post-transaction holding shows he maintains a substantial equity position in the company following the tax-related sale.

Was the Abeona (ABEO) CEO’s stock sale executed in a single trade or multiple trades?
The filing notes the reported price is a weighted average across multiple trades. Shares were sold in several transactions, at prices ranging from $6.86 to $7.04 per share, all contributing to the total 67,971 shares sold.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Seshadri Vishwas
(Last)(First)(Middle)
6555 CARNEGIE AVE., 4TH FLOOR
(Street)
CLEVELAND OHIO 44103
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/09/2026S(1)67,971D$6.9637(2)1,306,108D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
/s/ Vishwas Seshadri07/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR